HB+ is proud to partner with the National Minority Health Association to help bring about health equity and close the disparity gap in health and healthcare for underserved, marginalized, hard-to-reach, and minority communities.

Omeza(r), a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today presented positive interim data from a diabetic foot ulcer (DFU) clinical trial showing that Omeza(r) OCM(tm) plus offloading of weight on the affected foot achieved a 91 percent area reduction (PAR) rate in DFUs within twelve weeks, and a 63 percent PAR within four weeks.

Read More